What is Raymond James’ Estimate for TSE:ONC FY2024 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at Raymond James cut their FY2024 earnings per share estimates for Oncolytics Biotech in a report issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings of ($0.44) per share for the year, down from their prior estimate of ($0.38). Raymond James currently has a “Moderate Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Stock Performance

Shares of ONC opened at C$1.38 on Friday. The stock has a market capitalization of C$106.07 million, a P/E ratio of -3.63 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. Oncolytics Biotech has a 1 year low of C$1.15 and a 1 year high of C$2.32. The company’s fifty day moving average is C$1.50 and its two-hundred day moving average is C$1.45.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.